BB Braveheart Bio, Inc. Stock: price and insider trades · United States · SEC (Form 4)Track the Braveheart Bio, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.9bn. The latest transaction was disclosed on 11 August 2026 (Acquisition). Among the most active insiders: Forbion Growth Opportunities Fund III Cooperatief U.A.. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 August 2026
All Executives19 Thresholds0 Prospectus0 Other0
Declarations 19 total
▲ Director · Executives · 7 Aug 2026
1,666,667 shares @ US$18.00 1.38% mcap 85.9% of flow Common Stock SEC:0000947871-26-000782:1
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
273,333 shares @ US$18.00 0.23% mcap 14.1% of flow Common Stock SEC:0000947871-26-000782:2
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
1,666,667 shares @ US$18.00 1.38% mcap 85.9% of flow Common Stock SEC:0000947871-26-000783:1
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
273,333 shares @ US$18.00 0.23% mcap 14.1% of flow Common Stock SEC:0000947871-26-000783:2
Canonical exit: 5 Nov 2026 (T+90) ● 10% Owner · Executives · 7 Aug 2026
9,132,420 shares Common Stock SEC:0001231919-26-000859:0
● Director · Executives · 7 Aug 2026
9,132,420 shares Common Stock SEC:0000947871-26-000782:0
● Director · Executives · 7 Aug 2026
9,132,420 shares Common Stock SEC:0000947871-26-000783:0
▲ 10% Owner · Executives · 7 Aug 2026
1,100,000 shares @ US$18.00 0.91% mcap 100.0% of flow Common Stock SEC:0001231919-26-000859:1
Canonical exit: 5 Nov 2026 (T+90) ● 10% Owner · Executives · 7 Aug 2026
7,420,091 shares Common Stock SEC:0001104659-26-093140:0
▲ Chief Development Officer · Executives · 7 Aug 2026
1,111 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000799:0
Canonical exit: 5 Nov 2026 (T+90) ▲ 10% Owner · Executives · 7 Aug 2026
1,920,000 shares @ US$18.00 53.3% of flow Common Stock SEC:0001193125-26-340528:2
Canonical exit: 5 Nov 2026 (T+90) ▲ 10% Owner · Executives · 7 Aug 2026
1,680,000 shares @ US$18.00 46.7% of flow Common Stock SEC:0001193125-26-340528:3
Canonical exit: 5 Nov 2026 (T+90) ▲ CEO and President · Executives · 7 Aug 2026
83,333 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000798:0
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
4,166 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000800:0
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
83,333 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000801:0
Canonical exit: 5 Nov 2026 (T+90) ▲ Chief Financial Officer · Executives · 7 Aug 2026
27,777 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000804:0
Canonical exit: 5 Nov 2026 (T+90) ▲ Director · Executives · 7 Aug 2026
55,555 shares @ US$18.00 100.0% of flow Common Stock SEC:0001470831-26-000796:0
Canonical exit: 5 Nov 2026 (T+90) ● 10% Owner · Executives · 7 Aug 2026
9,132,420 shares 0Common Stock SEC:0001193125-26-340528:0
● 10% Owner · Executives · 7 Aug 2026
7,990,867 shares 0Common Stock SEC:0001193125-26-340528:1
About Braveheart Bio, Inc. Braveheart Bio, Inc. is a biotechnology company focused on developing innovative treatments for serious diseases. It is listed on the XNAS market.